Golimumab
From Ganfyd
rINN: Golimumab
Other Names
Simponi®
Pharmacological Information
Web information on Golimumab
Relevant Clinical Literature
UK Guidance
Regulatory Literature
Other Literature
Please read pharmacological data limitations
Other Wikis
Medpedia on Golimumab (Less technical, good quality control)
Wikipedia on Golimumab (Less technical, ? quality control)
Contents |
Introduction
A TNF-alpha blocker.
Clinical Use
Indications
Administration
Clinical Issues
Contra-indications
Cautions and Interactions
Side effects
- Hypersensivity
- Fever
- Nausea
- Abdominal pain
- Heart failure
- Headache
- Pruritis
- Depression
- SLE like syndrome
- Blood dyscrasias
 |
|
- Infections, including severe sepsis (odds ratio for serious infection 2.0 (95% CI, 1.3-3.1), number needed to harm 59 (95% CI, 39-125) within a treatment period of 3 to 12 months).
- Malignancy (odds ratio for malignancy 3.3 (95% CI, 1.2-9.1) number needed to harm 154 (95% CI, 91-500) for 1 additional malignancy within period of 6 to 12 months), including an association with hepatosplenic T-cell lymphoma in patients also on mercaptopurines.
References to side-effects[5] [6]
Special advice
Pharmacology
See adalimumab for a very similar therapeutic antibody.
References
- ↑ Kay J, Matteson EL, Dasgupta B, Nash P, Durez P, Hall S, Hsia EC, Han J, Wagner C, Xu Z, Visvanathan S, Rahman MU. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis and rheumatism. 2008 Apr; 58(4):964-75.(Link to article – subscription may be required.)
- ↑ Inman RD, Davis JC, Heijde D, Diekman L, Sieper J, Kim SI, Mack M, Han J, Visvanathan S, Xu Z, Hsu B, Beutler A, Braun J. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis and rheumatism. 2008 Nov; 58(11):3402-12.(Link to article – subscription may be required.)
- ↑ Theis VS, Rhodes JM. Review article: minimizing tuberculosis during anti-tumour necrosis factor-alpha treatment of inflammatory bowel disease. Alimentary pharmacology & therapeutics. 2008 Jan 1; 27(1):19-30.(Link to article – subscription may be required.)
- ↑ Lees CW, Wallace WAH, Satsangi J. Resolution of Non-small-Cell Lung Cancer after Withdrawal of Anti-TNF Therapy. NEJM 2008;359:320-1
- ↑ Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA : the journal of the American Medical Association 2006;295(19):2275-85. (Direct link – subscription may be required.)
- ↑ Rosh JR, Gross T, Mamula P, Griffiths A, Hyams J. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: A cautionary tale? Inflamm Bowel Dis 2007. (Direct link – subscription may be required.)
- ↑ Wenzel SE, Barnes PJ, Bleecker ER, Bousquet J, Busse W, Dahlén SE, Holgate ST, Meyers DA, Rabe KF, Antczak A, Baker J, Horvath I, Mark Z, Bernstein D, Kerwin E, Schlenker-Herceg R, Lo KH, Watt R, Barnathan ES, Chanez P. A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. American journal of respiratory and critical care medicine. 2009 Apr 1; 179(7):549-58.(Link to article – subscription may be required.)
